Nuance Pharma

We Are A Specialty Care
Biopharma Company

Committed To Bringing Transformational Therapies
To Patients In China And Asia

Read More

Read More
Fit For Purpose

We Transcend Clinical Application Insights That Drive Our
Clinical Development Strategy Through A Dual Wheel Model
Of Our Integrated Commercial Platform And Late Stage
Clinical Pipeline

Read More

Read More
Specialty Care
Boutique

We Focus On Developing First-in-Class Innovative Pipeline
To Address Unmet Medical Needs In Respiratory For The
Vast Patient Community In Asia
Asia Pac Vision

We Are Passionate About Exploring APAC Business Opportunities
And Have Substantive Progress In Our Asian Expansion Strategy
Bringing Therapies That Are More Accessible To People In China And Asia

Our Area Of Focus

We Have Developed A Differentiated Matrix Of Commercial Products And Innovative Pipeline Across Respiratory, Emergency Care, Iron Deficiency Anemia, Pain Management

Highlights

Founded by Mark Lotter in 2014, Nuance deploys the Dual Wheel model that develops a leading innovative pipeline, while maintaining a self-sustainable commercial operation in both China and Asia

5^PRODUCTS

COMMERCIAL
4^PIPELINE

LATE STAGE CLINICAL
400⁺

EMPLOYEES WORLDWIDE

Our Transformative Journey

2023

Completed dosing of First Patient in Ensifentrine China phase 3 trial for COPD

Read More
2022

Licensed in allergy alleviation / virus prevention nasal spray Bentrio™ from Altamira Therapeutics

Read More
2021

Licensed in First-in-Class COPD dual MOA PDE 3&4 inhibitor Ensifentrine from Verona Pharma
Licensed in neonatal RDS drug / device combo Aerofact™ from Aerogen Pharma
Acquired Sino Health with access to 3 emergency care products and a GSP license in Zhuhai

Read More
2020

Licensed in post-operative pain product Ketorolac (NTM-001) from Neumentum
Raised US$ 181 million Series D equity funding

Read More
2019

Acquired NIFEREX Iron Polysaccharide Complex Capsules

Read More
2018

Established partnership with Aerogen Pharma on nebulizer device
Accumulatively raised US$ 80 million equity funding

Read More
2014

Mr. Mark Lotter founded Nuance Pharma in Shanghai

Read More

2023

2022

2021

2020

2019

2018

2014

2023
2022
2021
2020
2019
2018
2014

News

2023-06-27

Verona Pharma Submits New Drug Application to US FDA for Ensifentrine for the Maintenance Treatment of COPD

Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces the submission of a New Drug Application (“NDA”) to the US Food and Drug Administration (“FDA”) for approval of ensifentrine for the maintenance treatment of patients with chron

CONTACT

021-32035318

info@nuancepharma.com

Suite 639, East Tower, No 1376 Nan Jing West Road, Shanghai. 200040

Privacy Statement Sitemap